title: Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice.
abstract: The sodium-dependent, high affinity serotonin [5-hydroxytryptamine (5-HT)] transporter (5-HTT) provides the primary mechanism for inactivation of 5-HT after its release into the synaptic cleft. To further evaluate the function of the 5-HTT, the murine gene was disrupted by homologous recombination. Despite evidence that excess extracellular 5-HT during embryonic development, including that produced by drugs that inhibit the 5-HTT, may lead to severe craniofacial and cardiac malformations, no obvious developmental phenotype was observed in the 5-HTT-/- mice. High affinity [3H]5-HT uptake was completely absent in 5-HTT-/- mice, confirming a physiologically effective knockout of the 5-HTT gene. 5-HTT binding sites labeled with [125I] 3 beta-(4'-iodophenyl)tropan-2 beta-carboxylic acid methyl ester were reduced in a gene dose-dependent manner, with no demonstrable binding in 5-HTT-/- mutants. In adult 5-HTT-/- mice, marked reductions (60-80%) in 5-HT concentrations were measured in several brain regions. While (+)-amphetamine-induced hyperactivity did not differ across genotypes, the locomotor enhancing effects of (+)-3, 4-methylenedioxymethamphetamine, a substituted amphetamine that releases 5-HT via a transporter-dependent mechanism, was completely absent in 5-HTT-/- mutants. Together, these data suggest that the presence of a functional 5-HTT is essential for brain 5-HT homeostasis and for 3,4-methylenedioxymethamphetamine-induced hyperactivity.
authors.affiliation: Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20892-1264, USA.
authors.forename: D
authors.initials: D
authors.lastname: Bengel
authors.forename: D L
authors.initials: DL
authors.lastname: Murphy
authors.forename: A M
authors.initials: AM
authors.lastname: Andrews
authors.forename: C H
authors.initials: CH
authors.lastname: Wichems
authors.forename: D
authors.initials: D
authors.lastname: Feltner
authors.forename: A
authors.initials: A
authors.lastname: Heils
authors.forename: R
authors.initials: R
authors.lastname: Mössner
authors.forename: H
authors.initials: H
authors.lastname: Westphal
authors.forename: K P
authors.initials: KP
authors.lastname: Lesch
mesh_terms: D000818:Animals; D001345:Autoradiography; D001923:Brain Chemistry / Q000187:drug effects* / Q000235:genetics; D002352:Carrier Proteins / Q000235:genetics*; D005260:Female; D018390:Gene Targeting; D005838:Genotype; D006706:Homeostasis / Q000187:drug effects* / Q000235:genetics; D008124:Locomotion / Q000187:drug effects* / Q000235:genetics; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics*; D026901:Membrane Transport Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D008845:Microinjections; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000172:deficiency / Q000235:genetics*; D012701:Serotonin / Q000235:genetics / Q000378:metabolism*; D050486:Serotonin Plasma Membrane Transport Proteins
chemical_list: D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D050486:Serotonin Plasma Membrane Transport Proteins; C493231:Slc6a4 protein, mouse; D012701:Serotonin; D018817:N-Methyl-3,4-methylenedioxyamphetamine